Neflamapimod slows DLB progression in Phase 2b; 89% worsening reduction in key subgroup

CervoMed Inc.

Primary endpoint CDR-SB mean change 52% lower with DP Batch B vs control; 82% lower in patients without AD co-pathology.
Within-patient comparison vs placebo: 1.12 point improvement on CDR-SB (p=0.005); ADCS-CGIC improved (p=0.004).
Risk of clinical progression reduced 75%; median time to progression extended from 16 weeks to 1.5 years.
Plasma GFAP reduced median -16.0 pg/mL (p<0.0001); reduction correlated with clinical treatment response.
Company planning Phase 3 registrational trial in patients with DLB starting H2 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.